TherapeuticsMD Announces Fourth Quarter and Full Year 2015 Financial Results

– Company to Present additional positive phase 3 data for TX-004HR at the ISSWSH annual meeting –

– Management to host conference call today at 4:30 p.m. EST –

BOCA RATON, Fla.--(BUSINESS WIRE)--Feb. 25, 2016-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced its fourth quarter and full year financial results for 2015.

2015 and Recent Developments

Net revenue for the company’s prescription prenatal vitamin business increased to approximately $20.1 million in 2015 compared with approximately $15.0 million for the prior year.
Net loss was approximately $85.1 million in 2015, compared with approximately $54.2 million for the prior year, reflecting investment in two phase 3 clinical trials for the company’s novel hormone therapy drug candidates.
Reported positive topline data from the Rejoice Trial, a phase 3 clinical trial of TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The results showed patients treated with TX-004HR achieved a statistically significant improvement over placebo across all four co-primary endpoints at all three doses evaluated. The validated co-primary endpoint data and additional secondary endpoint results related to vaginal dryness are scheduled to be presented this week at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting 2016. A summary of these data is included below in this press release.
Exited over 1,400 of the 1,750 patients enrolled in the Replenish Trial, a phase 3 clinical trial of TX-001HR, a combination estradiol and progesterone drug candidate, for the treatment of moderate to severe vasomotor symptoms due to menopause. Topline results are currently anticipated late in the fourth quarter of 2016.
The company’s intellectual property portfolio grew to a current total of 122 patent filings, including 72 international filings, with one allowed and 14 issued U.S. patents.
Presented two posters at North American Menopause Society (NAMS) of the company’s transdermal progesterone candidate, TX-005HR, and the company’s transdermal estradiol and progesterone candidate, TX-006HR, demonstrating tissue penetration and target organ activity in a preclinical study.
Strengthened relationships with key medical, pharmacy, patient and industry organizations worldwide.
Ended the year with approximately $64.7 million in cash and no debt, which was further strengthened by an equity offering in January 2016 that generated approximately $135 million of net proceeds to fund commercialization activities for both of the company’s late stage product candidates and other development activities.

“2015 was a breakthrough year for our company, as we reported positive topline phase 3 data from the Rejoice Trial for TX-004HR, the first of our two novel pipeline candidates in the women’s health arena,” said TherapeuticsMD CEO Robert G. Finizio. “Based on those compelling results, we are preparing to file an NDA before June 30, while we also expect topline data late in the fourth quarter of 2016 from our Replenish Trial for TX-001HR. We believe we are well positioned from a financial, clinical and commercial standpoint to execute on our goals in 2016 and create significant value for shareholders by advancing our pipeline and preparing to launch our first novel hormone product for women, if approved.”

Summary of 2015 Financial Results

For the year ended December 31, 2015, net revenue increased approximately 34 percent to approximately $20.1 million compared with approximately $15.0 million for the prior year. Net revenue for the fourth quarter of 2015 was approximately $5.6 million compared with net revenue of approximately $4.3 million for the prior year’s quarter. Revenue growth during the fourth quarter was primarily driven by a change in product mix and an increase in the average net sales price of the company’s prenatal vitamin products and revenue growth during the full year was primarily driven by an increase in the number of units sold and an increase in the average sales price of the company’s prenatal vitamin products.

Cost of goods sold increased to approximately $4.5 million for the full year 2015, compared with approximately $3.7 million in the prior year.

Total operating expenses for the fourth quarter and full year 2015 included research and development (R&D) expenses and sales, general and administrative expenses (SG&A). R&D expenses for the full-year 2015 were approximately $72.0 million compared with approximately $43.2 million for the prior year, primarily as a result of an increase in costs related to the company’s phase 3 clinical trials for TX-001HR and TX-004HR and an increase in scale-up and manufacturing activities primarily related to TX-001HR. R&D expenses during the fourth quarter of 2015 were $13.3 million compared to $14.2 million during the prior year’s quarter, reflecting a significant decline in the company’s clinical trial costs, partially offset by an increase in scale-up and manufacturing activities to support commercialization. SG&A expenses for the full-year 2015 were approximately $28.7 million compared with approximately $22.1 million for the prior year, reflecting an increase in human resources related costs, increased consulting and professional costs, increased insurance cost and increased sales and marketing expenses. SG&A expenses for the fourth quarter of 2015 were approximately $8.6 million compared with approximately $5.5 million for the prior year’s quarter, primarily as a result of increased human resource related costs, as well as increased sales and marketing and office expenses.

Non-operating income remained insignificant for the full year 2015 and 2014 and included interest income and other miscellaneous items of income and expense for both periods.

Net loss for the full year 2015 was approximately $85.1 million, or $0.49 per basic and diluted share, compared with approximately $54.2 million, or $0.36 per basic and diluted share, for the full year 2014. Net loss in the fourth quarter of 2015 was approximately $17.5 million, or $0.10 per basic and diluted share, compared with approximately $16.3 million, or $0.10 per basic and diluted share, for the fourth quarter of 2014.

At December 31, 2015, cash on hand was approximately $64.7 million, compared with approximately $51.4 million at December 31, 2014.

Phase 3 Data Results Presented at ISSWSH Annual Meeting 2016

TherapeuticsMD also announced that data from the phase 3 Rejoice Trial would be presented at the ISSWSH Annual Meeting 2016 taking place February 25-28 in Charleston, South Carolina. The poster to be presented includes validated co-primary endpoint results from the Rejoice Trial and secondary endpoint data that demonstrate the effect of TX-004HR on severity of vaginal dryness as compared with placebo at week 12.

Based on the company’s ongoing analyses of the Rejoice Trial data, statistical significance of the results for the co-primary endpoint of severity of participants' self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA has slightly improved for all three doses from the topline results previously reported. The secondary endpoint result for vaginal dryness was also statistically significant for all three doses evaluated in the Rejoice Trial.

Statistical Significance of Results for Co-Primary Endpoints
(Based on LS Mean Change from Baseline to Week 12 Compared to Placebo)
	25 mcg	10 mcg	4 mcg
Superficial Cells	P < 0.0001	P < 0.0001	P < 0.0001
Parabasal cells	P < 0.0001	P < 0.0001	P < 0.0001
Vaginal pH	P < 0.0001	P < 0.0001	P < 0.0001
Severity of Dyspareunia	P < 0.0001	P < 0.0001	P = 0.0149
Statistical Significance of Results for Secondary Endpoint of Severity of Vaginal Dryness (Based on LS Mean Change from Baseline to Week 12 Compared to Placebo)
Severity of Dryness	P < 0.0001	P < 0.0001	P = 0.0014
LS= Least Squares

Conference Call Today

As previously announced, TherapeuticsMD will host a conference call today to discuss these financial results and provide a business update. Details for the call are:

Date:		Thursday, February 25, 2016
Time:		4:30 p.m. EST
Telephone Access (US):		866-665-9531
Telephone Access (International):		724-987-6977
Access Code for All Callers:		45870409

Additionally, a live webcast can be accessed on the company’s website, www.therapeuticsmd.com, on the Home Page or under the “Investors & Media” section. A digital recording of the conference call will be available for replay beginning two hours after the call's completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 45870409.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins under the vitaMedMD^® and BocaGreenMD^® brands. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com and www.bocagreenmd.com.

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company’s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; the company’s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.

THERAPEUTICSMD, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

		December 31,
		2015			2014
ASSETS
Current Assets:
	Cash	$	64,706,355		$	51,361,607
	Accounts receivable, net of allowance for doubtful accounts
	of $81,910 and $59,753, respectively		3,049,715			2,154,217
	Inventory		690,153			1,182,113
	Other current assets		2,233,897			1,537,407
	Total current assets		70,680,120			56,235,344

Fixed assets, net			198,592			63,293

Other Assets:
	Intangible assets, net		1,615,251			1,228,588
	Prepaid expense		1,109,883			1,427,263
	Security deposit		125,000			125,000
	Total other assets		2,850,134			2,780,851
	Total assets	$	73,728,846		$	59,079,488

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
	Accounts payable	$	3,126,174		$	6,327,129
	Other current liabilities		7,539,526			3,840,639
	Deferred revenue		-			522,613
	Total current liabilities		10,665,700			10,690,381


Commitments and Contingencies

Stockholders' Equity:
	Preferred stock - par value $0.001; 10,000,000 shares authorized;
	no shares issued and outstanding		-			-
	Common stock - par value $0.001; 350,000,000 and 250,000,000
	shares authorized; 177,928,041 and 156,097,019 issued
	and outstanding, respectively		177,928			156,097
	Additional paid-in capital		282,712,078			182,982,846
	Accumulated deficit		(219,826,860	)		(134,749,836	)
	Total stockholders' equity		63,063,146			48,389,107
	Total liabilities and stockholders' equity	$	73,728,846		$	59,079,488

THERAPEUTICSMD, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

		Three Months Ended December 31,						Year Ended December 31,
		2015			2014			2015			2014			2013


Revenues, net		$	5,629,740		$	4,257,647		$	20,142,898		$	15,026,219		$	8,775,598

Cost of goods sold			1,235,978			879,535			4,506,673			3,671,803			1,959,597

Gross profit			4,393,762			3,378,112			15,636,225			11,354,416			6,816,001

Operating expenses:
	Sales, general, and administrative		8,631,238			5,514,057			28,721,236			22,124,072			19,014,837
	Research and development		13,253,472			14,166,789			72,042,774			43,218,938			13,551,263
	Depreciation and amortization		18,000			12,558			62,400			52,467			58,145

	Total operating expenses		21,902,710			19,693,404			100,826,410			65,395,477			32,624,245

Operating loss			(17,508,948	)		(16,315,292	)		(85,190,185	)		(54,041,061	)		(25,808,244	)

Other income and (expenses)
	Miscellaneous income, net		23,991			3,158			95,719			46,569			34,544
	Interest income		2,280			9,553			17,442			37,309			27,234
	Financing costs		-			-			-			(260,027	)		(1,503,922	)
	Interest expense		-			-			-			-			(1,165,981	)
	Loan guaranty costs		-			-			-			-			(2,944	)
	Total other income (expense)		26,271			12,711			113,161			(176,149	)		(2,611,069	)

Loss before income taxes			(17,482,677	)		(16,302,581	)		(85,077,024	)		(54,217,210	)		(28,419,313	)

Provision for income taxes			-			-			-			-			-

Net loss		$	(17,482,677	)	$	(16,302,581	)	$	(85,077,024	)	$	(54,217,210	)	$	(28,419,313	)

Loss per share, basic and diluted:

Net loss per share, basic and diluted		$	(0.10	)	$	(0.10	)	$	(0.49	)	$	(0.36	)	$	(0.22	)

Weighted average number of common
	shares outstanding, basic and diluted		177,876,462			156,054,938			173,174,229			149,727,228			127,569,731

THERAPEUTICSMD, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS


		Year Ended December, 31,
		2015			2014			2013

CASH FLOWS FROM OPERATING ACTIVITIES
	Net loss	$	(85,077,024	)	$	(54,217,210	)	$	(28,419,313	)
	Adjustments to reconcile net loss to net cash used in
	operating activities:
	Depreciation		29,959			28,987			47,883
	Amortization of intangible assets		32,441			23,480			10,262
	Provision for (recovery of) doubtful accounts		22,157			(5,436	)		(15,493	)
	Amortization of debt discount		-			-			1,102,680
	Share-based compensation		7,189,699			4,970,312			3,844,155
	Amortization of deferred financing costs		-			260,027			1,451,934
	Loan guaranty costs		-			-			2,944
	Changes in operating assets and liabilities:
	Accounts receivable		(917,656	)		(458,028	)		(1,068,619	)
	Inventory		491,960			(138,495	)		571,592
	Other current assets		(773,532	)		680,281			(1,386,319	)
	Other assets		(17,442	)		(37,309	)		(565,706	)
	Accounts payable		(3,200,955	)		4,212,912			472,851
	Deferred revenue		(522,613	)		(1,079,967	)		457,828
	Other current liabilities		3,698,887			239,450			2,875,320
	Other liabilities		-			-			(150,068	)

	Net cash used in operating activities		(79,044,119	)		(45,520,996	)		(20,768,069	)

CASH FLOWS FROM INVESTING ACTIVITIES
	Patent costs		(419,104	)		(586,480	)		(439,034	)
	Purchase of fixed assets		(165,257	)		(30,962	)		(40,790	)
	Refund (payment) of security deposit		-			10,686			(103,737	)

	Net cash used in investing activities		(584,361	)		(606,756	)		(583,561	)

CASH FLOWS FROM FINANCING ACTIVITIES
	Proceeds from sale of common stock, net of costs		91,374,649			42,771,353			78,650,353
	Proceeds from exercise of options		1,232,579			345,746			30,910
	Proceeds from exercise of warrants		366,000			181,000			-
	Proceeds bank line of credit		-			-			500,000
	Repayment of bank line of credit		-			-			(500,000	)
	Repayment of notes payable		-			-			(4,691,847	)

	Net cash provided by financing activities		92,973,228			43,298,099			73,989,416

	Increase (decrease) in cash		13,344,748			(2,829,653	)		52,637,786
	Cash, beginning of period		51,361,607			54,191,260			1,553,474
	Cash, end of period	$	64,706,355		$	51,361,607		$	54,191,260

	SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

	Cash paid for interest	$	-		$	-		$	212,853

	Cash paid for income taxes	$	-		$	-		$	-

	SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:

	Warrants issued for financing	$	-		$	-		$	1,711,956

	Warrants issued for services	$	-		$	-		$	462,196

View source version on businesswire.com: http://www.businesswire.com/news/home/20160225006507/en/

Source: TherapeuticsMD, Inc.

TherapeuticsMD, Inc.
Investors:
Dan Cartwright, 561-961-1900
Chief Financial Officer
Dan.Cartwright@TherapeuticsMD.com